Home pageFTRE • NASDAQ
add
Covance
6,26 $
After Hours:(0,00%)0,00
6,26 $
Data e ora chiusura: 2 mag, 16:01:29 GMT-4 · USD · NASDAQ · Disclaimer
Chiusura precedente
6,08 $
Intervallo giornaliero
6,06 $ - 6,35 $
Intervallo annuale
4,77 $ - 37,47 $
Cap di mercato
566,78 Mln USD
Volume medio
2,76 Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | dic 2024info | Variazione Y/Y |
---|---|---|
Entrate | 697,00 Mln | -1,79% |
Spese di gestione | 168,90 Mln | 13,43% |
Utile netto | -61,20 Mln | -12,29% |
Margine di profitto netto | -8,78 | -14,32% |
Utili per azione | 0,18 | -5,26% |
EBITDA | -7,20 Mln | -241,18% |
Aliquota fiscale effettiva | 1,34% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | dic 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 118,50 Mln | 9,12% |
Totale attivo | 3,58 Mld | -17,39% |
Totale passivo | 2,22 Mld | -15,34% |
Patrimonio netto totale | 1,36 Mld | — |
Azioni in circolazione | 90,20 Mln | — |
Prezzo/valore contabile | 0,40 | — |
Redditività dell'attivo | -1,93% | — |
Rendimento sul capitale | -2,65% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | dic 2024info | Variazione Y/Y |
---|---|---|
Utile netto | -61,20 Mln | -12,29% |
Liquidità di esercizio | 17,10 Mln | -7,07% |
Contanti da investimenti | 3,50 Mln | 138,89% |
Contanti da finanziamenti | -1,10 Mln | 85,71% |
Flusso di cassa netto | 13,20 Mln | 175,00% |
Flusso di cassa libero | 90,21 Mln | 1.006,90% |
Informazioni
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Fondazione
apr 1996
Sito web
Dipendenti
15.810